Goldman Sachs Group Inc. reduced its position in Teligent, Inc. (NASDAQ:TLGT) by 15.7% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 102,701 shares of the company’s stock after selling 19,071 shares during the period. Goldman Sachs Group Inc.’s holdings in Teligent were worth $802,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Teligent by 10.4% in the first quarter. Vanguard Group Inc. now owns 1,976,891 shares of the company’s stock worth $15,440,000 after buying an additional 185,624 shares in the last quarter. Columbus Circle Investors boosted its position in shares of Teligent by 62.6% in the first quarter. Columbus Circle Investors now owns 196,430 shares of the company’s stock worth $1,534,000 after buying an additional 75,595 shares in the last quarter. State Street Corp boosted its position in shares of Teligent by 11.7% in the fourth quarter. State Street Corp now owns 647,583 shares of the company’s stock worth $4,280,000 after buying an additional 67,935 shares in the last quarter. Eagle Global Advisors LLC bought a new position in shares of Teligent during the first quarter worth $309,000. Finally, Renaissance Technologies LLC bought a new position in shares of Teligent during the first quarter worth $198,000. 62.88% of the stock is currently owned by hedge funds and other institutional investors.

Teligent, Inc. (NASDAQ TLGT) traded up 1.12% during trading on Wednesday, reaching $6.34. The company’s stock had a trading volume of 54,925 shares. The firm’s market cap is $338.50 million. The stock’s 50 day moving average is $8.12 and its 200-day moving average is $8.01. Teligent, Inc. has a 52 week low of $5.74 and a 52 week high of $9.54.

Teligent (NASDAQ:TLGT) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.02 by $0.04. The firm had revenue of $18.40 million for the quarter, compared to the consensus estimate of $20.11 million. Teligent had a positive return on equity of 1.49% and a negative net margin of 11.36%. The firm’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.02 earnings per share. On average, equities research analysts forecast that Teligent, Inc. will post $0.09 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Goldman Sachs Group Inc. Has $802,000 Stake in Teligent, Inc. (TLGT)” was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.watchlistnews.com/goldman-sachs-group-inc-has-802000-stake-in-teligent-inc-tlgt/1494950.html.

A number of equities analysts recently weighed in on TLGT shares. Zacks Investment Research cut Teligent from a “hold” rating to a “sell” rating in a research note on Thursday, July 6th. Deutsche Bank AG reissued a “hold” rating and issued a $9.00 price target (up previously from $8.00) on shares of Teligent in a research note on Monday, July 17th. BidaskClub cut Teligent from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. Canaccord Genuity started coverage on Teligent in a research note on Monday, July 31st. They set a “buy” rating and a $11.00 target price on the stock. Finally, ValuEngine cut Teligent from a “hold” rating to a “sell” rating in a research note on Tuesday, July 25th. Three analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $9.00.

About Teligent

Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.

Want to see what other hedge funds are holding TLGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teligent, Inc. (NASDAQ:TLGT).

Institutional Ownership by Quarter for Teligent (NASDAQ:TLGT)

Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.